Life Sciences Tools and Services
Company Overview of Knome, Inc.
Knome, Inc., a life sciences company, provides human genome interpretation software and services for academic, pharmaceutical, and biotech researchers in the United States and internationally. It offers tools and solutions that help researchers, drug developers, and clinicians determine the genetic basis of human disease and drug response. The company provides knomeCLINIC, a software suite that helps medical researchers and clinicians interpret human genomes for biological relevance; kGAP, a cloud-enabled genome informatics engine that automates the process of standardizing, distilling, annotating, and comparing sequence data; Desktop interpretation-support applications that allow medical re...
25 First Street
Cambridge, MA 02141
Founded in 2007
Key Executives for Knome, Inc.
Co-Founder and Chairman of Scientific Advisory Board
Compensation as of Fiscal Year 2013.
Knome, Inc. Key Developments
Knome Introduces KnoSYS(TM)100
Sep 27 12
Knome, Inc. announced that it is taking orders for the knoSYS(TM)100, the first plug-and-play, fully integrated hardware and software system designed to help researchers in medical and academic institutions interpret human whole genomes. The knoSYS(TM)100 was developed to help geneticists discover relevant genetic variation, investigate diseases of unknown cause, and create next generation in silico gene tests. Units will begin shipping in the fourth quarter of 2012. knoSYS(TM)100, the first plug-and-play, fully integrated hardware and software system designed to help researchers in medical and academic institutions interpret human whole genomes. The knoSYS(TM)100 was developed to help geneticists discover relevant genetic variation, investigate diseases of unknown cause, and create next generation in silico gene tests. Starting at $125,000, the knoSYS(TM)100 is based on Knome's big data informatics technology. The system will accept next generation sequence data from sequencers, including those sold by Illumina, Life Technologies and Complete Genomics.
Knome Appoints Heidi L. Rehm to Scientific Advisory Board
Jul 9 12
Knome, Inc. announced that a clinical geneticist, Heidi Rehm, PhD, has joined the company's scientific advisory board. Dr. Rehm is a board-certified clinical geneticist who is currently Chief Laboratory Director of the Laboratory for Molecular Medicine at Partners HealthCare Center for Personalised Genetic Medicine as well as Assistant Professor of Pathology and Director of the Clinical Molecular Genetics Training Program at Harvard Medical School.
Knome, Inc. Starts its Early Technology Access Program for knomeCLINIC
Jun 11 12
Knome, Inc. announced the start of its early technology access program for knomeCLINIC, a software suite designed to help medical researchers and clinicians interpret human genomes for biological relevance. Clinics accepted into the early access program will be given installation priority, access to pilot programs and pre-release prototypes, and the ability to influence knomeCLINIC's feature set upon general release. On release, knomeCLINIC will consist of the components like: kGAP(TM): a robust, scalable, and extensible informatics and annotation platform that serves as the technical foundation for knomeCLINIC's desktop interpretation-support applications. kGAP accepts raw sequence data from major sequencing platforms--generating standardized, annotated data sets. Desktop interpretation-support applications: applications that allow medical researchers and clinicians to identify the genetic variants, genes and pathways that underlie disease and tumor growth--helping them conduct longitudinal studies, better understand both rare and common diseases, and evaluate treatment regimens. Knowledge database: a database of Knome-curated and harmonized reference data from more than a dozen sources, containing over 100,000 genotype-phenotype associations. Curation applications: software that enables researchers, physician practice groups, and medical institutions to curate and prioritize genotype-phenotype associations, whether publically available or self-generated.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|